{
 "id": "metastatic-breast-cancer",
 "name": "Metastatic Breast Cancer",
 "aliases": [
  "Metastatic breast cancer"
 ],
 "acronyms": [],
 "bodySystem": "cancer",
 "parent": "breast cancer",
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 3
 },
 "funds": [
  {
   "fund": "Metastatic Breast Cancer",
   "organization": "CancerCare",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed).",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "fund": "Metastatic Breast Cancer",
   "organization": "Good Days",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed).",
   "readOn": "2026-11-08",
   "source": "https://mygooddays.org/patients/diseases-covered/"
  },
  {
   "fund": "Metastatic breast cancer",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 7000,
   "insuranceTypes": [
    "Any health insurance"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "ABEMACICLIB",
   "pages": [
    {
     "brand": "Verzenio",
     "url": "https://omnirx.org/negotiated-drugs/verzenio"
    }
   ],
   "labelSentence": "... an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22be4bc0de-0fdc-4d46-8d25-be43c79e6a06%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Lilly Cares",
     "url": "https://omnirx.org/assistance/lilly-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available Medications: list of all products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "PALBOCICLIB",
   "pages": [
    {
     "brand": "Ibrance",
     "url": "https://omnirx.org/negotiated-drugs/ibrance"
    }
   ],
   "labelSentence": "... for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2289a142d5-7e61-48bf-9e77-e2cd124c4792%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Cancer Drug Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/cancer-drug-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 7871,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "RIBOCICLIB",
   "pages": [
    {
     "brand": "Kisqali",
     "url": "https://omnirx.org/negotiated-drugs/kisqali"
    }
   ],
   "labelSentence": "... for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy;",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22aaeaef94-f3f5-4367-8ea2-b181d7be2da8%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Alpelisib",
   "pages": [
    {
     "brand": "Piqray",
     "url": "https://omnirx.org/medicines/piqray"
    }
   ],
   "labelSentence": "... hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22b20b4e18-7a4b-4500-a08f-06c6dab0ee5b%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Capivasertib",
   "pages": [
    {
     "brand": "Truqap",
     "url": "https://omnirx.org/medicines/truqap"
    }
   ],
   "labelSentence": "HR positive, HER2 negative locally advanced or metastatic breast cancer • in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22d698c106-2322-401e-b738-cbd83c843ecf%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Olaparib",
   "pages": [
    {
     "brand": "Lynparza",
     "url": "https://omnirx.org/medicines/lynparza"
    }
   ],
   "labelSentence": "... for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22741ff3e3-dc1a-45a6-84e5-2481b27131aa%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Cancer Drug Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/cancer-drug-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Elacestrant HCl",
   "pages": [
    {
     "brand": "Orserdu",
     "url": "https://omnirx.org/medicines/orserdu"
    }
   ],
   "labelSentence": "... estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22aa66ae5c-2bd2-4444-8178-b55651e054ef%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tucatinib",
   "pages": [
    {
     "brand": "Tukysa",
     "url": "https://omnirx.org/medicines/tukysa"
    }
   ],
   "labelSentence": "Metastatic Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22f27eb1b9-b7fc-424e-988f-84dd7bb195a3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways (Pfizer Patient Assistance Program)",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": false,
     "note": null,
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [
  {
   "fund": "American Cancer Society Cancer Care Continuity Fund",
   "organization": "Patient Advocate Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.patientadvocate.org/connect-with-services/financial-aid-funds/"
  },
  {
   "need": "testing",
   "fund": "Cancer genetic and genomic testing",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "need": "home care",
   "fund": "Cancer Home Care Services",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "behavioral health",
   "fund": "Cancer-Related Behavioral Health",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "pain management",
   "fund": "Cancer-Related Pain Management",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare CAR-T Caregiver Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare Caregiver Financial Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "clinical trial costs",
   "fund": "CancerCare Clinical Trial Financial Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "transportation",
   "fund": "CancerCare Gets You There - Transportation Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "behavioral health",
   "fund": "Oncology Caregiver Behavioral Health Fund (Accepting phone applications only)",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  }
 ],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}